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Abstract
Autosomal dominant progressive external ophthalmoplegia (adPEO) is a late-onset,
Mendelian mitochondrial disorder characterised by paresis of the extraocular muscles,
ptosis, and skeletal-muscle restricted multiple mitochondrial DNA (mtDNA) deletions.
Although dominantly inherited, pathogenic variants in POLG, TWNK and RRM2B are
among the most common genetic defects of adPEO, identification of novel candidate
genes and the underlying pathomechanisms remains challenging. We report the clinical,
genetic and molecular investigations of a patient who presented in the seventh decade
of life with PEO. Oxidative histochemistry revealed cytochrome c oxidase-deficient
fibres and occasional ragged red fibres showing subsarcolemmal mitochondrial accumu-
lation in skeletal muscle, while molecular studies identified the presence of multiple
mtDNA deletions. Negative candidate screening of known nuclear genes associated
with PEO prompted diagnostic exome sequencing, leading to the prioritisation of a
novel heterozygous c.547G>C variant in GMPR (NM_006877.3) encoding guanosine
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monophosphate reductase, a cytosolic enzyme required for maintaining the cellular bal-
ance of adenine and guanine nucleotides. We show that the novel c.547G>C variant cau-
ses aberrant splicing, decreased GMPR protein levels in patient skeletal muscle,
proliferating and quiescent cells, and is associated with subtle changes in nucleotide
homeostasis protein levels and evidence of disturbed mtDNA maintenance in skeletal
muscle. Despite confirmation of GMPR deficiency, demonstrating marked defects of
mtDNA replication or nucleotide homeostasis in patient cells proved challenging. Our
study proposes that GMPR is the 19th locus for PEO and highlights the complexities of
uncovering disease mechanisms in late-onset PEO phenotypes.
K E YWORD S
GMPR, mitochondrial DNA maintenance, multiple mtDNA deletions, PEO, whole exome
sequencing
1 | INTRODUCTION
Autosomal dominant progressive external ophthalmoplegia (adPEO) is
a mitochondrial DNA (mtDNA) maintenance disorder characterised by
restriction of the extraocular muscles, ptosis, and secondary, clonally
expanded skeletal muscle-restricted multiple mtDNA deletions.1 The
spectrum of PEO clinical phenotypes are broad, ranging from isolated
PEO to fatal, multisystem PEO-plus disorders,2 while pathogenic,
dominantly inherited variants of POLG (MIM 174763), TWNK (MIM
606075) and RRM2B (MIM 604712) are among the most common
causes of adulthood to late-onset PEO.3 Although next-generation
DNA sequencing technologies have enhanced its genetic diagnosis
and led to the identification of novel genes, PEO candidate variant
prioritisation is highly challenging due to mild phenotypic expression
at a subcellular level.
Maintaining a balance of all four deoxyribonucleotides (dNTPs), the
building blocks for DNA synthesis, is essential for mtDNA replication
and is intricately regulated through synthesis and degradation.4 In pro-
liferating (dividing) cells, dNTPs for mtDNA are predominantly
synthesised de novo in the cytosol through ribonucleotide reduction by
ribonucleotide reductase (RNR), which is composed of the large R1 and
small R2 subunits.5 A small proportion of dNTPs are also derived from
recycling via the cytosolic and mitochondrial deoxyribonucleotide sal-
vage pathways. In quiescent (non-dividing) cells, nuclear DNA replica-
tion is suspended. As a consequence, cytosolic de novo synthesis is
strongly reduced. DNA replication in mitochondria continues, instead
relying upon the rate-limiting enzymes thymidine kinase 2 (TK2) and
deoxyguanosine kinase (DGUOK), via the mitochondrial deoxyribonu-
cleotide salvage pathway6 and limited cytosolic de novo synthesis
through the alternative RNR containing the p53R2 subunit.7-10
Pathogenic variants in ABAT (MIM 137150), DGUOK (MIM 601465),
MPV17 (MIM 137960), RRM2B, SUCLA2 (MIM 603921), SUCLG1 (MIM
611224), TK2 (MIM 188250) and TYMP (MIM 131222), encoding pro-
teins involved in dNTP homeostasis, are known to cause quantitative
(depletion) or qualitative (multiple deletions) disorders of mtDNA mainte-
nance.11-21 Of these, RRM2B and TYMP encode cytosolic enzymes,
which support an assumption that there is mixing of cytosolic and
mitochondrial dNTP pools. This is further supported by the identifi-
cation of pyrimidine nucleotide carriers 1 and 2 (PNC1/2) and
equilibrative nucleotide transporter 1 (ENT1), which exchange pyrimi-
dine or purine nucleotides from the cytosol through the mitochondrial
membrane to the matrix.22-25 Therefore, a cytosolic nucleotide metabo-
lism defect can negatively influence DNA replication in mitochondria
and lead to defects in mtDNA maintenance.
Here, we present a patient with a novel heterozygous c.547G>C
variant in GMPR (MIM 139265) encoding the cytosolic purine metabo-
lism enzyme guanosine monophosphate reductase with late onset
PEO. Our functional data corroborated the mild phenotypic expres-
sion leading us to propose that GMPR is a rare, novel candidate locus
for adulthood-onset adPEO with disordered mtDNA maintenance.
2 | METHODS
2.1 | Histopathology, biochemical and molecular
genetic studies
Skeletal muscle biopsy was subjected to haemotoxylin and Eosin (H&E)
staining, cytochrome c oxidase (COX), succinate dehydrogenase (SDH),
sequential COX-SDH histochemical reactions and quadruple immuno-
fluorescence assay analysis.26 Whole mitochondrial genome sequencing
was performed to exclude pathogenic variants. The presence of mtDNA
rearrangements and mtDNA copy number was assessed using
established diagnostic long-range PCR27 and real-time PCR assays.28
2.2 | Whole exome sequencing, candidate variant
prioritisation and genetic studies
Exome capture of fragmented patient blood genomic DNA was
attained and WES was performed as previously described.29 Details
of WES analysis, candidate variant prioritisation, Sanger sequencing
and cDNA studies in skeletal muscle and cultured fibroblasts are out-
lined in Supporting Information.
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2.3 | In vitro studies
In vitro experiments using hGMPR2 and hGMPR2-G183R mutant were
performed as previously described.30,31 Details of cloning, mutagenesis,
overexpression and purification are outlined in Supporting Information.
2.4 | Cell culture
Cells were incubated at 37C with 5% CO2. Cultured patient and
control fibroblasts were grown in minimum essential medium (MEM)
with 10% foetal bovine serum, 1% MEM vitamins, 1% non-essential
amino acids, 50 U ml−1 penicillin, 50 μg ml−1 streptomycin, 1 mM sodium
pyruvate solution, 25 mg ml−1 uridine solution and 2 mM L-glutamine.
Quiescent (non-dividing) cells were generated to repress cytosolic
de novo nucleotide synthesis and limit the supply of dNTPs to mitochon-
dria. Once cultured fibroblast cell lines were confluent, the culture
medium was replaced with MEM containing 0.1% dialysed foetal bovine
serum. Cells were incubated with quiescent medium for 10-14 days, with
medium replenished every 2-3 days. Guanosine (G) was supplemented in
quiescent medium at a final concentration of 100 μM for the whole
duration of the serum starvation period.
2.5 | Cellular and sub-mitochondrial fractionation
HeLa and HEK293T cells were fractionated as described previously,32
with few modifications (Supporting Information).
2.6 | Immunoblotting
Cell lysates (50 μg) and skeletal muscle homogenate (25-50 μg) were
separated by 10% or 12% SDS-PAGE and electrophoretically trans-
ferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad).
Primary antibodies are listed in Table SS1. Both GMPR primary anti-
bodies (ab118751, Abcam; SAB1101144, Sigma) were specific to
GMPR but not GMPR2.
For colocalisation studies, 30 μg of protein from each fraction
were analysed by immunoblotting using primary antibodies as follows:
GMPR (ab118751, Abcam), GDH (custom made), NDUFB8 (as described
above), eIF4E (9742, Cell Signaling Technology), AIF (4642, Cell Signaling
Technology) and EF-Tu (custom made).
Following incubation with horseradish peroxidase-conjugated second-
ary antibodies (Dako) for 1 hour at room temperature, detected proteins
were visualisedwith ClarityWestern ECL substrate (Bio-Rad) or Amersham
ECL Prime Western Blotting Detection Reagent (GE Healthcare, Life
Sciences), and signals were visualised using the Bio-Rad ChemiDoc MP
with Image Lab software according tomanufacturer's guidelines.
2.7 | Confocal microscopy and nucleoid organisation
Confocal microscopy of proliferating and quiescent cells was per-
formed as previously described.33,34 Further details and assessment of
nucleoid organisation in skeletal muscle are outlined in Supporting
Information.
2.8 | In vitro mitochondrial protein synthesis
Newly synthesised mitochondrial proteins were assessed as described
previously.35
2.9 | Cytosolic and mitochondrial dNTP pool
determination
Approximately 1.5 × 108 fibroblasts under quiescent conditions were
homogenised in 210 mM mannitol, 70 mM sucrose, 10 mM Tris HCl,
pH 7.5, 0.2 mM EGTA, and 0.5 mg ml−1 BSA using a 23-gauge needle
(total fraction). Homogenates were then centrifuged at 1000g for
5 minutes, and the crude mitochondrial fraction in the supernatant
was pelleted at 19000 g for 20 minutes. dNTPs were extracted from
total homogenates or mitochondrial pellets and dNTP pools were
measured by the polymerase-based method as described previously.36
2.10 | Quantitative and qualitative assessments of
mtDNA in proliferating and quiescent cells
DNA was extracted using DNeasy Blood & Tissue Kit (Qiagen), according
to the manufacturer instructions. Quantification of relative mtDNA copy
number in proliferating and quiescent cells was performed as described
previously.36 Long-range PCR was performed as described previously,27
with increasing concentrations of DNA template.
3 | RESULTS
3.1 | Case report
The patient is a 73-year-old female, the only child born to non-
consanguineous parents, who presented with a history of late adulthood-
onset PEO. At 60 years old, she underwent corrective strabismus surgery
but complained of diplopia post-surgery. She also reported mild bilateral
ptosis at 69 years old. Upon clinical examination she had marked PEO
with subtle asymmetry, mild asymmetric ptosis (right>left), exotropia of
the right eye and mild orbicularis oculi weakness (Figure 1A). Mild facial
and proximal muscle weakness (MRC 4+/5) were also noted. Brain MRI
was normal but there was no comment on the extraocular muscles. There
was no reported family history of any eye movement or neuromuscular
disorder. She has three asymptomatic children.
3.2 | A skeletal muscle biopsy from the patient
displays hallmarks of a mtDNA maintenance disorder
A muscle biopsy revealed approximately 15% cytochrome c oxidase
(COX)-deficient fibres and occasional ragged-red fibres demonstrating
subsarcolemmal mitochondrial accumulation (Figure 1B). Long-range
PCR of skeletal muscle DNA revealed multiple mtDNA deletions
(Figure 1C), confirmed by quantitative single-fibre real-time PCR in
which the majority of COX-deficient fibres were shown to harbour
clonally expanded mtDNA rearrangements involving the MTND4 gene
(Figure 1D). Quadruple OXPHOS immunofluorescence assay of
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F IGURE 1 Clinical, histopathologic and molecular characterisation of a patient harbouring a novel heterozygous c.547G>C GMPR variant.
A, Ophthalmological features of the patient with PEO harbouring a novel heterozygous GMPR variant, highlighting bilateral ptosis and frontalis
muscle hyperactivity. B, A skeletal muscle biopsy from the patient was subjected to (a) COX, (b) SDH, (c) sequential COX-SDH histochemical
reactions and (d) haemotoxylin and eosin (H&E) staining. Scale bar represents 100 μM. C, 13-kb long-range PCR assay of skeletal muscle mtDNA
demonstrating multiple mtDNA deletions in the patient (lane 4) compared with aged-matched controls (lanes 1 and 2) and a patient with a single,
large-scale mtDNA deletion (lane 3). D, Quantitative single-fibre real-time PCR assay reveals that the majority of COX-deficient fibres exhibit
clonally expanded multiple mtDNA deletions involving theMTND4 gene. E, Mitochondrial respiratory chain expression profile showing NDUFB8
(complex I), COX-I (complex IV) and porin levels in individual patient skeletal muscle fibres. Each dot represents an individual muscle fibre, colour
coded according to mitochondrial mass (very low, blue; low, light blue; normal, light orange; high, orange; and very high, red). Black dashed lines
represent the SD limits for the classification of fibres. Lines adjacent to the X- and Y-axis represent the levels of NDUFB8 and COX-I (beige,
normal; light beige, intermediate (+); light blue, intermediate (−); and blue, negative]. F, Family pedigree and Sanger sequencing confirmation of
the novel c.547G>C GMPR variant in the index case
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individual muscle fibres showed a greater proportion of fibres with
reduced NDUFB8 (complex I) levels and a population of fibres with
equal loss of NDUFB8 and MT-COI (complex IV) proteins (Figure 1E),
suggestive of a mtDNA maintenance disorder.26
3.3 | Identification of a novel heterozygous
c.547G>C GMPR variant
Candidate screening of nuclear genes associated with adulthood-onset
PEO and multiple mtDNA deletions (POLG, NM_002693.2; RRM2B,
NM_015713.4; SLC25A4, NM_001151.4; TWNK, NM_021830.5;
POLG2, NM_007215.4; TK2, NM_004614.4; RNASEH1, NM_002936.5)
failed to detect pathogenic or likely pathogenic variants, prompting
whole exome sequencing.
We implemented a custom-variant filtering strategy that antici-
pated either a dominant or recessive aetiology, prioritising rare or novel
variants in nuclear genes encoding DNA replisome machinery or
mitochondrial-localised proteins.37 Assessment of rare or novel variants
in known nuclear genes associated with disordered mtDNA main-
tenance, including genes screened diagnostically, did not reveal
pathogenic or likely pathogenic variants. Our analysis identified a
novel heterozygous c.547G>C variant in exon 5 of the GMPR
(NM_006877.3) gene encoding guanosine monophosphate reduc-
tase. GMPR catalyses the NADPH-dependent deamination of the
ribonucleotide guanosine monophosphate (GMP) to inosine mono-
phosphate (IMP) in the cytosol, thereby maintaining purine nucleo-
tide pools.38 The novel variant was absent from 378 in-house
controls and GnomAD (http://gnomad.broadinstitute.org/). Sanger
sequencing confirmed the variant, but unfortunately familial
segregation studies were not possible (Figure 1F). Analysis of copy
number variants (CNVs) identified by WES did not disclose
rearrangements encompassing GMPR. A single nucleotide polymor-
phism array was also negative for additional rare variants in GMPR
or rearrangements. We also submitted GMPR to the GeneMatcher
initiative (https://genematcher.org/), however this failed to deliver
matching submissions.
In the absence of other candidate variants and the known function
of GMPR, we prioritised further studies of the novel GMPR variant.
3.4 | The novel c.547G>C variant causes aberrant
splicing and GMPR depletion
The c.547G>C GMPR variant was initially predicted to cause a
p.Gly183Arg missense change. Our in vitro data assessing a human
GMPR2-G183R mutant confirmed that the Gly183 residue is critical
for enzymatic activity (Figure SS3) as it is close to the active site.39
However, further experiments of the c.547G>C variant, occurring at
the last nucleotide of exon 5, showed that it led to aberrant splicing of
the GMPR transcript. We assessed splicing by sequencing skeletal
muscle-derived cDNA from the patient and an age-matched control.
Following RT-PCR, we observed only wild-type products corresponding
to full-length GMPR cDNA from control and patient skeletal muscle
(Figure 2A). Next, we assessed splicing by sequencing fibroblast-derived
cDNA from patient and control fibroblasts. Only wild-type PCR prod-
ucts were observed in patient and control fibroblasts without emetine
treatment (Figure SS1A). However, a short, abnormal PCR product was
observed in patient cells after 10-hour emetine treatment to inhibit
nonsense mediated decay. Sequencing of the abnormal PCR product
revealed a secondary trace with skipping of exon 5, removing nucleo-
tides r.466 to r.547 (r.466_547del) from the transcript (Figure SS1B).
The predicted effect at the protein level was a frameshift deletion, p.
Ala156Valfs*17.
Immunoblotting revealed that steady-state GMPR protein levels
were decreased to approximately 34% in patient skeletal muscle
homogenate, which is relative to age-matched controls (Figure 2B).
GMPR protein levels were also decreased in proliferating (dividing)
and quiescent (non-dividing) patient and control cell lysates
(Figure SS2B). These data were consistent with nonsense-mediated
decay of the mutant transcript. Interestingly, GMPR protein levels
were reduced in both control and patient cells in quiescent state,
suggesting that GMPR activity is reduced in cells that have exited the
cell-cycle.
3.5 | Patient skeletal muscle and fibroblasts do not
show marked OXPHOS defects
Core OXPHOS subunit protein levels were unaffected in skeletal mus-
cle homogenate (Figure SS2A), demonstrating that the reduced com-
plex I and IV subunit levels in individual muscle fibres observed by
quadruple immunofluorescence assay were not necessarily readily
detectable at a tissue homogenate level. OXPHOS subunit protein
levels were also unaffected in proliferating and quiescent patient cell,
relative to control cells (Figure S2B).
3.6 | GMPR is a cytosolic purine metabolism enzyme
GMPR is not a known mitochondrial protein and is not listed in the
MitoCarta compendium.40 With the exception of PSort, all localisation
algorithms (TargetP, MitoProt II, Predotar, and MitoFates) predicted a
low probability of mitochondrial localisation and no targeting pre-
sequence. We performed subfractionation and immunoblotting of
HEK293T and HeLa cells to experimentally confirm GMPR localisation.
Immunoblotting of whole cell and mitochondrial-free lysates using
markers for the mitochondrial matrix (GDH, EF-Tu), intermembrane
space (AIF), inner membrane (NDUFB8) and cytosol (eIF4E) showed
that GMPR does not localise to mitochondria and is present only in the
cytosol (Figure 2C).
3.7 | Subtle alterations in nucleotide homeostasis
protein levels and mtDNA maintenance markers in
patient skeletal muscle
We postulated that GMPR deficiency would increase the levels of its
substrate GMP, leading to increased GTP levels and therefore altering
dNTP pools. Hence, this could perturb the purine balance and, in turn,
affect the de novo synthesis of dNTPs. We assessed protein levels of
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the RNR subunits, R1 and p53R2, and nucleotide transporters PNC1
and AAC1 (Figure 3A, left panel). Steady-state levels of the large R1
subunit of the RNR were mildly increased, whereas levels of the small
p53R2 subunit and AAC1, the mitochondrial ADP/ATP carrier, were
unaffected. By contrast, PNC1, a mitochondrial pyrimidine nucleotide
carrier, was decreased in patient skeletal muscle.
mtDNA levels were at the high range of normal (data not shown)
whereas the level of mtDNA packaging protein transcription factor A
(TFAM) was markedly decreased in GMPR patient skeletal muscle
(Figure 3A, right panel) and LONP1, which degrades TFAM not bound
to mtDNA, was elevated. Levels of the mitochondrial DNA polymer-
ase gamma large subunit (POLG) were unchanged.
F IGURE 2 Genetic characterisation of the novel GMPR variant in skeletal muscle. A, Amplification of control and patient skeletal muscle-
derived cDNA across GMPR exons 3-7 and sequencing chromatograms showing wild-type PCR products from control and patient skeletal
muscle. NT, No template. B, Steady-state GMPR protein levels in control and patient skeletal muscle homogenate. SDHA was used as a loading
control. C, Subfractionation of (a) HEK293T and (b) HeLa cells subjected to immunoblotting with a GMPR antibody and markers for each
subfraction: GDH and EF-Tu—mitochondrial matrix; AIF—mitochondrial inner membrane space; NDUFB8—mitochondrial inner membrane;
eIF4E—cytosol. All subfractions were prepared from the same HeLa or HEK293T lysate [Colour figure can be viewed at wileyonlinelibrary.com]
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F IGURE 3 Assessment of nucleotide homeostasis and mtDNA machinery markers in skeletal muscle and cytosolic and mitochondrial
dNTP measurements in quiescent cells. A, Steady-state proteins levels of nucleotide homeostasis and mtDNA maintenance markers in
control and GMPR patient skeletal muscle homogenates. GAPDH, α-tubulin and porin were used as loading controls. OXPHOS subunits
SDHB (CII) and ATP5A (CV) were also used as markers to confirm protein loading. B, Cytosolic (left) and mitochondrial (right) dNTP levels in
quiescent GMPR mutant and control fibroblasts. C, Relative mtDNA copy number in GMPR patient and control proliferating (P) and
quiescent (Q) fibroblasts. Relative mtDNA copy number was expressed as fold change relative to one proliferating control [Colour figure can
be viewed at wileyonlinelibrary.com]
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3.8 | Cytosolic and mitochondrial dNTP levels in
quiescent GMPR patient cells are unaltered
To further test our hypothesis, we quantified cytosolic and mitochon-
drial dNTPs (dCTP, dGTP, and dTTP) in quiescent patient and control
cells. dATPs were not measurable with our PCR-based method. How-
ever, there were no changes in either cytosolic or mitochondrial dNTP
levels, relative to controls (Figure 3B). These results indicate that dNTP
pools are unaffected in the in vitro cultured patient cells. According to
this, mtDNA maintenance was not altered, as mtDNA copy number
was also normal in proliferating and quiescent patient cells (Figure 3C)
and deletions were undetectable (see the next section).
To investigate whether the possible presence of mtDNA deletions
in patient cells could alter mitochondrial protein synthesis, we assessed
de novo synthesis of mtDNA-encoded OXPHOS subunits in proliferat-
ing and quiescent cells by 35S-methionine labelling. This showed a slight
decrease of nascent mitochondrial proteins in quiescent patient cells,
while proliferating cells were unaffected (Figure SS2C).
3.9 | Mitochondrial networks and nucleoid
morphology in proliferating and quiescent patient cells
To investigate mtDNA organisation, we fixed and labelled sections
of control and GMPR patient skeletal muscle with anti-TOM20
and anti-DNA antibodies. Patient skeletal muscle fibres were
characterised by an increased number of enlarged nucleoids, com-
pared with an age-matched control (Figure 4A). Furthermore,
there was increased TOM20 staining in patient fibres that were
suggestive of mitochondrial biogenesis. Hence, enlarged nucleoids
in patient skeletal muscle fibres could be secondary to increased
mitochondrial biogenesis.
F IGURE 4 Nucleoid and mitochondrial network morphology in skeletal muscle, mtDNA depletion-repletion studies and guanosine
supplementation in non-dividing cells. A, Confocal images of patient and control muscle sections labelled with antibodies to the
mitochondrial membrane protein TOM20 (red) and DNA (green). B, Non-dividing patient and control cells were depleted of mtDNA
using the intercalating agent ethidium bromide for 14 days. Ethidium bromide was then removed and mtDNA replenishment was followed
for 14 days. Relative mtDNA copy number was expressed as fold change relative to one control. Student's t test was performed for
statistical comparison between control and patient cell mtDNA copy number. C,D, Patient and control fibroblasts were put into
quiescence by serum starvation for 14 days with or without guanosine supplementation. mtDNA copy number (C) and mtDNA deletions
(D) were assessed at the end of the treatment. Increasing amounts of DNA (10, 20, 40 and 80 μg) were used as template for long-
range PCR
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Confocal microscopy in proliferating patient cells revealed slightly
elongated mitochondria and increased branching, while the size and dis-
tribution of nucleoids were normal compared to controls (Figure WS4).
Similarly, nucleoids also appeared normal in fixed non-dividing patient
cells; length and branching of mitochondria were not quantitatively
assessed (Supplemental Figure S5). Therefore, this suggests that altered
mitochondrial protein synthesis in GMPR patient cells does not reflect a
defect of mtDNA organisation or qualitative changes of the mtDNA
sequence.
3.10 | Mitochondrial DNA replication is not
perturbed in GMPR patient fibroblasts
Since cytosolic and mitochondrial dNTP levels and relative mtDNA
copy number were normal in patient fibroblasts, we challenged
mtDNA maintenance by performing a mtDNA depletion-repletion
experiment to assess the rate of mtDNA replication in quiescent cells.
mtDNA was depleted using the intercalating agent ethidium bromide
for 14 days, and the replenishment of mtDNA was followed for a
further 14 days. mtDNA copy number was restored to the original
level in patient cells as effectively as control cells (Figure 4B), which
suggested no impairment of mtDNA replication.
In the absence of overt mtDNA aberrations in patient fibroblasts, we
postulated that challenging the patient cells could stress the phenotype
and reveal mild defects in mtDNA replication. By increasing the concen-
tration of the GMPR substrate, GMP, this could lead to increased GTP
and therefore alter the ratio of GTP/dGTP pools in cells. To do so, we
supplemented the cell culture medium with guanosine (Guo), which in
the cell is readily converted to GMP, for 14 days of serum starvation. Fol-
lowing supplementation, quantitative real-time PCR did not show mtDNA
depletion in patient cells (Figure 4C). In addition, long-range PCR did not
detect the presence of large-scale mtDNA rearrangements (Figure 4D).
4 | DISCUSSION
Here, we demonstrate an apparent heterozygous mutation in GMPR,
as another important, albeit rare cause of late-onset PEO. We show
that decreased GMPR protein levels in patient skeletal muscle and
proliferating and quiescent fibroblasts could be attributed to aberrant
splicing and nonsense-mediated decay of the mutant, leading to very
mild alterations in nucleotide homeostasis. Crucially, the c.547G>C
variant in this report is novel and conceivably pathogenic.
GMPR encodes guanosine monophosphate reductase, an evolu-
tionarily conserved enzyme from humans to bacteria that catalyses
the conversion of the ribonucleotide GMP to IMP, a precursor ribonu-
cleotide for the synthesis of purine nucleotides.38 GMPR is highly
expressed in skeletal and cardiac muscle and kidney tissue,41 but here-
tofore, is not a known mitochondrial protein and has not been associ-
ated with human disease. We experimentally confirmed that GMPR is
a cytosolic nucleotide metabolism enzyme, similar to thymidine phos-
phorylase and p53R2, encoded by TYMP and RRM2B, respectively,
which are known mtDNA maintenance disorder loci.
Reduced expressed of GMPR has been previously evident in skel-
etal muscle from early-onset, TK2-related mtDNA depletion patients42
and multiple mtDNA deletions in muscle (Figure 1C,D) are a patholog-
ical hallmark of mtDNA disorders. Therefore, the expectation was that
the GMPR variant caused mtDNA disease owing to perturbed dNTP
pools. However, detailed molecular studies suggest that the underlying
disease mechanism could be different from any of the well-established
mtDNA disorders. The mitochondrial dNTP pools of GMPR mutant
cells are normal and mtDNA copy number is maintained in tissues and
proliferating cells. Nor does exit from the cell cycle induce mtDNA
depletion, as it does in many other cases and mtDNA replication is not
impeded even when the demand is high (Figure 4B). In general, mtDNA
copy number is directly proportional to the level of TFAM, as observed
in the TFAM-knockout mouse model.43 However, in GMPR patient
skeletal muscle, this is not the case, therefore providing an additional
mtDNA abnormality. What substitutes TFAM is not known but the
change is strongly suggestive of some change in its substrate, that is,
the mtDNA sequence or its topology. Moreover, the alternative
mtDNA packaging arrangement could be the cause of the accumulated
mtDNA deletions and could account for the modest decrease in its
expression (Supplemental Figure S2B).
Notwithstanding all of the above, decreased levels of the mito-
chondrial pyrimidine transporter PNC1 in patient skeletal muscle sug-
gests that there is a nucleotide homeostasis problem. One reason
pyrimidine uptake might need to be reduced when the underlying
problem relates to purine biosynthesis, would be to maintain an
appropriate balance among the dNTP pools, to preserve mtDNA
integrity.36,44
Finally, we considered whether the depletion of GMPR protein
levels may alter the ratio of GTP to dGTP in GMPR patient tissue and
cells due to increased levels of the GMPR substrate, GMP. Recent evi-
dence suggests that altered rNTP:dNTP ratio leads to aberrant ribonu-
cleotide incorporation in mtDNA that can, in turn, cause stalling of
DNA replication in mitochondria.45,46 Cultured cell lines from patients
with autosomal recessive MPV17, DGUOK or TK2 defects that pres-
ented reduced levels of mitochondrial dGTP (MPV17, DGUOK) or
dCTP (TK2) revealed increased incorporation of rGMP or rCMP in
mtDNA.46 Aberrant ribonucleotide incorporation into mtDNA can
underlie the pathogenesis of multiple mtDNA deletions, as shown in
brain tissue from Mpv17-knockout mice, where increased levels of
rGMP incorporation in mtDNA was associated with multiple mtDNA
deletions.45 Thus, tissue specific changes to the ratio of rNTP:dNTPs
could explain the presence of mtDNA depletion or multiple deletions
in mtDNA maintenance disorders. Decreased GMPR protein or loss of
activity in skeletal muscle could increase incorporation of rGMP in
mtDNA to deleterious levels, stalling replication and causing multiple
mtDNA deletions, but with normal dGTP levels; similar to brain tissue
from Mpv17-knockout mice.45 However, rNTP:dNTP ratios in cell
lines or post-mitotic tissue derived from patients with dominantly
inherited variants causing late-onset mtDNA maintenance disorders
have not been investigated to date.
Overall, our functional data corroborate the subtle clinical pheno-
type and support our assertion that GMPR now represents another
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important nuclear-encoded gene associated with PEO and multiple
mtDNA deletions; the finding and characterisation of other patients
will strengthen this association.
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